RU2020109775A - Комплексная терапия - Google Patents
Комплексная терапия Download PDFInfo
- Publication number
- RU2020109775A RU2020109775A RU2020109775A RU2020109775A RU2020109775A RU 2020109775 A RU2020109775 A RU 2020109775A RU 2020109775 A RU2020109775 A RU 2020109775A RU 2020109775 A RU2020109775 A RU 2020109775A RU 2020109775 A RU2020109775 A RU 2020109775A
- Authority
- RU
- Russia
- Prior art keywords
- mixture
- compound
- solvate
- hydrate
- formula
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims 69
- 239000000203 mixture Substances 0.000 claims 50
- 150000001875 compounds Chemical class 0.000 claims 46
- 230000000155 isotopic effect Effects 0.000 claims 35
- 229940002612 prodrug Drugs 0.000 claims 35
- 239000000651 prodrug Substances 0.000 claims 35
- 150000003839 salts Chemical class 0.000 claims 35
- 239000012453 solvate Substances 0.000 claims 35
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 25
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 21
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 21
- 239000003112 inhibitor Substances 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims 14
- 229960000106 biosimilars Drugs 0.000 claims 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000003444 follicular lymphoma Diseases 0.000 claims 5
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 229960004641 rituximab Drugs 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims 2
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 108700042805 TRU-015 Proteins 0.000 claims 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- -1 heteroalkenylene Chemical group 0.000 claims 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims 2
- 229960003347 obinutuzumab Drugs 0.000 claims 2
- 229950005751 ocrelizumab Drugs 0.000 claims 2
- 229960002450 ofatumumab Drugs 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229950004593 ublituximab Drugs 0.000 claims 2
- 229950000815 veltuzumab Drugs 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical group CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545427P | 2017-08-14 | 2017-08-14 | |
| US62/545,427 | 2017-08-14 | ||
| PCT/US2018/046742 WO2019036489A1 (en) | 2017-08-14 | 2018-08-14 | COMBINATION THERAPY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020109775A true RU2020109775A (ru) | 2021-09-16 |
| RU2020109775A3 RU2020109775A3 (OSRAM) | 2022-03-25 |
Family
ID=65362803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020109775A RU2020109775A (ru) | 2017-08-14 | 2018-08-14 | Комплексная терапия |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11351176B2 (OSRAM) |
| EP (1) | EP3668507A4 (OSRAM) |
| JP (1) | JP2020531414A (OSRAM) |
| KR (1) | KR20200041358A (OSRAM) |
| CN (1) | CN111212643A (OSRAM) |
| AU (1) | AU2018318129A1 (OSRAM) |
| BR (1) | BR112020002984A2 (OSRAM) |
| CA (1) | CA3072476A1 (OSRAM) |
| IL (1) | IL272560A (OSRAM) |
| MA (1) | MA49921A (OSRAM) |
| MX (1) | MX2020001727A (OSRAM) |
| RU (1) | RU2020109775A (OSRAM) |
| SG (1) | SG11202001258UA (OSRAM) |
| WO (1) | WO2019036489A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2691384T3 (en) | 2011-03-28 | 2017-01-16 | Mei Pharma Inc | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND THEIR SUBSTANCES CONCERNING THE USE OF THE USE |
| MX2019013862A (es) | 2017-05-23 | 2020-01-20 | Mei Pharma Inc | Terapia de combinacion. |
| EP3668507A4 (en) | 2017-08-14 | 2021-05-12 | MEI Pharma, Inc. | Combination therapy |
| MA53236A (fr) * | 2018-08-14 | 2021-06-23 | Mei Pharma Inc | Traitement des malignités des lymphocytes b |
| AU2019322858A1 (en) * | 2018-08-14 | 2021-04-01 | Mei Pharma, Inc. | Combination therapy |
| US20210196725A1 (en) * | 2018-08-14 | 2021-07-01 | Mei Pharma, Inc. | Treatment of relapsed follicular lymphoma |
| TW202038945A (zh) * | 2018-12-21 | 2020-11-01 | 美商梅製藥公司 | 組合療法 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0711804A3 (de) | 1994-11-14 | 1999-09-22 | Ciba SC Holding AG | Kryptolichtschutzmittel |
| JP3512911B2 (ja) | 1995-07-11 | 2004-03-31 | 富士写真フイルム株式会社 | 紫外線吸収剤前駆体化合物、それを含有する感光性樹脂組成物及び画像形成方法 |
| DE69821633T2 (de) | 1997-07-24 | 2004-12-16 | Zenyaku Kogyo K.K. | Heterozyklische verbindungen und antitumormittel, das diese als aktiven wirkstoff enthält |
| JPH11174638A (ja) | 1997-12-08 | 1999-07-02 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| EP1278748B1 (en) | 2000-04-25 | 2011-03-23 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| AU6513701A (en) | 2000-05-30 | 2001-12-11 | Advanced Res & Tech Inst | Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways |
| EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| DE10207037A1 (de) | 2002-02-20 | 2003-08-28 | Bayer Cropscience Gmbh | 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| EP1485381B8 (en) | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine as inhibitors of protein kinases |
| DE60314603T2 (de) | 2002-03-15 | 2008-02-28 | Vertex Pharmaceuticals Inc., Cambridge | Zusammensetzungen brauchbar als protein-kinase-inhibitoren |
| EP1485380B1 (en) | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines as inhibitors of protein kinases |
| US7091343B2 (en) | 2002-03-15 | 2006-08-15 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US20070191402A1 (en) | 2002-05-17 | 2007-08-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of searching substrate having antidiabetic activity |
| DK1557415T3 (da) | 2002-10-25 | 2012-09-17 | Zenyaku Kogyo Kk | Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens |
| US7423148B2 (en) | 2002-11-21 | 2008-09-09 | Chiron Corporation | Small molecule PI 3-kinase inhibitors and methods of their use |
| WO2005028467A1 (en) | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
| KR101164541B1 (ko) | 2004-01-12 | 2012-07-10 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 선택적 키나제 저해제 |
| CA2561406C (en) | 2004-03-31 | 2012-07-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and anti-malignant-tumor agent comprising the same as effective component |
| NZ552946A (en) | 2004-08-26 | 2010-09-30 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| TW200628463A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
| WO2006053227A2 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| ES2395196T3 (es) | 2005-03-11 | 2013-02-11 | Zenyaku Kogyo Kabushikikaisha | Agente inmunosupresor que comprende un compuesto heterocíclico como ingrediente activo |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0525080D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US20070244110A1 (en) | 2006-04-14 | 2007-10-18 | Zenyaku Kogyo Kabushiki Kaisha | Treatment of prostate cancer, melanoma or hepatic cancer |
| KR101402474B1 (ko) | 2006-04-26 | 2014-06-19 | 제넨테크, 인크. | 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물 |
| EP2041139B1 (en) | 2006-04-26 | 2011-11-09 | F. Hoffmann-La Roche AG | Pharmaceutical compounds |
| DK2050749T3 (en) | 2006-08-08 | 2018-01-08 | Chugai Pharmaceutical Co Ltd | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF |
| US20090325954A1 (en) | 2006-09-14 | 2009-12-31 | Sam Butterworth | 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032060A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032036A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| EP2069330A1 (en) | 2006-09-14 | 2009-06-17 | AstraZeneca AB | 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032064A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
| WO2008032027A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
| WO2008032077A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
| WO2008032041A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives having inhibitory activity against pi3k enzymes |
| CN101563340A (zh) | 2006-09-14 | 2009-10-21 | 阿斯利康(瑞典)有限公司 | 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物 |
| WO2008032089A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032091A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| KR20090108124A (ko) | 2007-02-06 | 2009-10-14 | 노파르티스 아게 | Ｐｉ 3-키나제 억제제 및 그의 사용 방법 |
| WO2008110891A2 (en) | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | New heterocyclic compounds |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| JP2010529193A (ja) | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
| AU2008273892A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| MY150993A (en) | 2007-10-05 | 2014-03-31 | Verastem Inc | Pyrimidine substituted purine derivatives |
| WO2009045174A1 (en) | 2007-10-05 | 2009-04-09 | S*Bio Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| JP5479912B2 (ja) | 2007-11-22 | 2014-04-23 | 全薬工業株式会社 | 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法 |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| WO2009093981A1 (en) | 2008-01-23 | 2009-07-30 | S Bio Pte Ltd | Triazine compounds as kinase inhibitors |
| US20090192176A1 (en) | 2008-01-30 | 2009-07-30 | Wyeth | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
| TW200938201A (en) | 2008-02-07 | 2009-09-16 | Chugai Pharmaceutical Co Ltd | Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof |
| US20110053907A1 (en) | 2008-03-27 | 2011-03-03 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
| RS55960B1 (sr) | 2008-05-23 | 2017-09-29 | Wyeth Llc | Triazinska jedinjenja kao inhibitori pi3 kinaze i mtor |
| US20110105500A1 (en) | 2008-06-27 | 2011-05-05 | S*Bio Pte Ltd. | Pyrazine substituted purines |
| EP2307414A4 (en) | 2008-07-07 | 2011-10-26 | Xcovery Holding Co Llc | SELECTIVE INHIBITORS OF PI3 KINASE ISOFORMS |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| ES2674719T3 (es) | 2008-11-13 | 2018-07-03 | Gilead Calistoga Llc | Terapias para neoplasias hematológicas |
| AU2010214440A1 (en) | 2009-02-12 | 2011-09-01 | Astellas Pharma Inc. | Hetero ring derivative |
| NZ595372A (en) | 2009-03-27 | 2013-11-29 | Vetdc Inc | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| WO2010110686A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy |
| SG182247A1 (en) | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| SG175708A1 (en) | 2009-05-27 | 2011-12-29 | Genentech Inc | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| AU2010266064A1 (en) | 2009-06-25 | 2012-01-19 | Amgen Inc. | 4H - pyrido [1, 2 - a] pyrimidin - 4 - one derivatives as PI3 K inhibitors |
| AU2010265971B2 (en) | 2009-06-25 | 2014-08-14 | Amgen Inc. | Heterocyclic compounds and their uses as inhibitors of PI3 K activity |
| EA201270051A1 (ru) | 2009-06-25 | 2012-05-30 | Амген Инк. | Гетероциклические соединения и их применения |
| EA201270013A1 (ru) | 2009-06-25 | 2012-06-29 | Амген Инк. | Гетероциклические соединения и их применение |
| EP2451802A1 (en) | 2009-07-07 | 2012-05-16 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| MX346042B (es) | 2010-08-10 | 2017-03-03 | Astellas Pharma Inc | Compuesto heterociclico. |
| JP2014500275A (ja) | 2010-12-06 | 2014-01-09 | フォリカ，インコーポレイテッド | 禿頭症を治療するため、および毛髪の成長を促進するための方法 |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| BR112013024909A2 (pt) | 2011-03-28 | 2019-09-24 | Mei Pharma Inc | composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k |
| DK2691384T3 (en) | 2011-03-28 | 2017-01-16 | Mei Pharma Inc | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND THEIR SUBSTANCES CONCERNING THE USE OF THE USE |
| EP2691388A1 (en) | 2011-03-28 | 2014-02-05 | MEI Pharma, Inc. | (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013006408A1 (en) | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| US9499474B2 (en) | 2011-11-11 | 2016-11-22 | Merck Patent Gmbh | Process for producing arylamines |
| EA029485B1 (ru) | 2012-08-09 | 2018-04-30 | Селджин Корпорейшн | Способы лечения рака, выбранного из лимфомы, лейкоза, миеломы, глиобластомы, рака ободочной и прямой кишки и печеночно-клеточной карциномы, с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона |
| WO2014055647A1 (en) | 2012-10-03 | 2014-04-10 | Mei Pharma, Inc. | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
| EP3756686A1 (en) * | 2012-11-02 | 2020-12-30 | TG Therapeutics Inc. | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor |
| WO2014141129A2 (en) | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
| EP2832358A1 (en) | 2013-08-02 | 2015-02-04 | Bionsil S.r.l. | Pharmaceutical kit for use in the treatment of colon and colorectal cancer |
| US10328080B2 (en) | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
| US20160331754A1 (en) * | 2014-01-20 | 2016-11-17 | Gilead Sciences, Inc. | Therapies for treating cancers |
| WO2015125085A1 (en) | 2014-02-19 | 2015-08-27 | Piramal Enterprises Limited | Compounds for use as gpr120 agonists |
| US9949971B2 (en) | 2014-06-17 | 2018-04-24 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor |
| LT3179991T (lt) | 2014-08-11 | 2021-11-10 | Acerta Pharma B.V. | Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai |
| US20170231995A1 (en) | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment |
| EP3262071B8 (en) | 2014-09-23 | 2022-05-18 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
| CN115925679A (zh) | 2014-12-24 | 2023-04-07 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
| TN2018000020A1 (en) | 2015-07-20 | 2019-07-08 | Genzyme Corp | Colony stimulating factor-1 receptor (csf-1r) inhibitors. |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| CA3001857A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| EP3487878A4 (en) | 2016-07-20 | 2020-03-25 | University of Utah Research Foundation | CAR-T CD229 LYMPHOCYTES AND METHODS OF USE |
| BR112019005337A2 (pt) | 2016-09-19 | 2019-08-27 | Mei Pharma Inc | terapia combinada |
| WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| MX2019013862A (es) | 2017-05-23 | 2020-01-20 | Mei Pharma Inc | Terapia de combinacion. |
| EP3668507A4 (en) | 2017-08-14 | 2021-05-12 | MEI Pharma, Inc. | Combination therapy |
| SG11202009137PA (en) | 2018-03-21 | 2020-10-29 | Mei Pharma Inc | Combination therapy |
| MA53236A (fr) | 2018-08-14 | 2021-06-23 | Mei Pharma Inc | Traitement des malignités des lymphocytes b |
| US20210196725A1 (en) | 2018-08-14 | 2021-07-01 | Mei Pharma, Inc. | Treatment of relapsed follicular lymphoma |
| TW202038945A (zh) | 2018-12-21 | 2020-11-01 | 美商梅製藥公司 | 組合療法 |
-
2018
- 2018-08-14 EP EP18846994.4A patent/EP3668507A4/en not_active Withdrawn
- 2018-08-14 JP JP2020507012A patent/JP2020531414A/ja active Pending
- 2018-08-14 BR BR112020002984-0A patent/BR112020002984A2/pt not_active Application Discontinuation
- 2018-08-14 CA CA3072476A patent/CA3072476A1/en active Pending
- 2018-08-14 WO PCT/US2018/046742 patent/WO2019036489A1/en not_active Ceased
- 2018-08-14 CN CN201880067022.6A patent/CN111212643A/zh active Pending
- 2018-08-14 KR KR1020207007476A patent/KR20200041358A/ko not_active Ceased
- 2018-08-14 SG SG11202001258UA patent/SG11202001258UA/en unknown
- 2018-08-14 US US16/639,088 patent/US11351176B2/en active Active
- 2018-08-14 RU RU2020109775A patent/RU2020109775A/ru unknown
- 2018-08-14 MX MX2020001727A patent/MX2020001727A/es unknown
- 2018-08-14 AU AU2018318129A patent/AU2018318129A1/en not_active Abandoned
- 2018-08-14 MA MA049921A patent/MA49921A/fr unknown
-
2020
- 2020-02-09 IL IL272560A patent/IL272560A/en unknown
-
2022
- 2022-05-02 US US17/734,345 patent/US20220265673A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200222415A1 (en) | 2020-07-16 |
| RU2020109775A3 (OSRAM) | 2022-03-25 |
| MX2020001727A (es) | 2020-03-20 |
| IL272560A (en) | 2020-03-31 |
| US11351176B2 (en) | 2022-06-07 |
| CN111212643A (zh) | 2020-05-29 |
| MA49921A (fr) | 2021-05-12 |
| WO2019036489A1 (en) | 2019-02-21 |
| SG11202001258UA (en) | 2020-03-30 |
| CA3072476A1 (en) | 2019-02-21 |
| EP3668507A4 (en) | 2021-05-12 |
| KR20200041358A (ko) | 2020-04-21 |
| US20220265673A1 (en) | 2022-08-25 |
| AU2018318129A1 (en) | 2020-03-26 |
| JP2020531414A (ja) | 2020-11-05 |
| EP3668507A1 (en) | 2020-06-24 |
| BR112020002984A2 (pt) | 2020-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020109775A (ru) | Комплексная терапия | |
| JP7270235B2 (ja) | ペンタアザ大環状環複合体による組み合わせ癌免疫療法 | |
| HRP20171727T1 (hr) | Novi terapeutici | |
| JP2017528462A5 (OSRAM) | ||
| RU2015118135A (ru) | Содержащие заместители бензольные соединения | |
| JP2020531414A5 (OSRAM) | ||
| CN110769837A (zh) | 与五氮杂大环状环配合物的联合癌症免疫疗法 | |
| CN120285177A (zh) | Hdac抑制剂和pd-1抑制剂的组合疗法 | |
| AU2014244333B2 (en) | Compositions comprising anti-CD38 antibodies and carfilzomib | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| RU2008150419A (ru) | ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ CDK | |
| JP2014510729A5 (OSRAM) | ||
| RU2017112048A (ru) | Синергистические комбинации ауристана | |
| US11246950B2 (en) | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | |
| HRP20220351T1 (hr) | 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene | |
| RU2017131158A (ru) | Конъюгат лиганда с цитотоксическим лекарственным средством, способ его получения и применение | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2014528464A5 (OSRAM) | ||
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| JP2025511852A (ja) | Ｐｄ－１阻害剤及びｓｉｋ３阻害剤に基づく併用療法 | |
| JP2020505468A5 (OSRAM) | ||
| RU2004136989A (ru) | Цианогуанидиновые пролекарства | |
| RU2004135307A (ru) | Производное эпотилона для лечения гепатомы и других раковых заболеваний | |
| JP2017515899A5 (OSRAM) | ||
| RU2004136991A (ru) | Цианогуанидиновые пролекарства |